ArticleMedicine2026
Diagnostic value of drug withdrawal observation in drug-induced liver injury: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re-exploration of the pharmacotherapeutic strategy for drug-induced liver injury: a narrative review.Frontiers in medicine · 2026Review
- Association Between Khat (Biomarker insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aims to assess the diagnostic value of drug withdrawal for drug-induced liver injury (DILI). Seventeen cases of suspected DILI were retrospectively analyzed at the time of initial diagnosis. Pertinent patient demographics such as gender, age, suspected causative drugs, initial serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels, and additional clinical parameters were documented. Subsequently, the suspected drugs were discontinued without the administration of liver-protective interventions, and the hepatic function of the patients was reassessed weekly. Based on the criteria of whether serum ALT/AST levels decreased by more than 50% from their respective baseline values after 1 week, patients were categorized into either the rapid decline group or the non-rapid decline group. This observation period was extended for 4 weeks, succeeded by a subsequent follow-up period of 4 weeks. Most patients recovered liver function within 3 weeks after drug withdrawal. The rapid decline group (12/12) recovered fully, compared to 4/5 in the non-rapid group. Liver enzyme levels (ALT/AST) differed significantly between groups over 4 weeks, with the rapid group showing a larger initial AST drop. All other factors like age and gender were similar. The time to disease recurrence was also comparable. A high DILI probability was confirmed in 16 of the 17 suspected cases, indicating a 94.11% diagnostic accuracy for DILI. In conclusion, this retrospective analysis underscores the potential of drug withdrawal as an effective management strategy for suspected DILI. The findings reveal that the cessation of suspected causative drugs, without the administration of liver-protective treatment, leads to recovery in hepatic function, as evidenced by the normalization of serum ALT and AST levels, contributing to the diagnosis of DILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.